Category Cancer Types

21
Dec

KCC researchers discover new pathways that drive metastatic prostate cancer

Elevated levels of Cyclin D1b could function as a novel biomarker of lethal metastatic disease in prostate cancer patients, according to a pre-clinical study published ahead of print on December 21 in the Journal of Clinical Investigation by researchers at the Kimmel Cancer Center at Jefferson. The group, headed by Karen E. Knudsen, Ph.D., Professor …

23
Oct

Dr. Renato Iozzo appointed as Editor-In-Chief of Matrix Biology

Renato Iozzo, M.D., Ph.D.,  a Professor of Pathology, Anatomy and Cell Biology at Thomas Jefferson University, has recently been appointed as Editor-in-Chief of the journal Matrix Biology beginning January 2013. This flagship journal is published by Elsevier and is affiliated with both the International Society for Matrix Biology and the American Society for Matrix Biology. …

22
Oct

NCI Awards ‘Provocative Questions’ Grant to Thomas Jefferson University Researcher Scott Waldman

Scott Waldman, M.D., Ph.D., chairman of the Department of Pharmacology and Experimental Therapeutics at Thomas Jefferson University, has been awarded one of the prestigious “Provocative Questions”  grants from the National Cancer Institute (NCI) , as part of the Institute’s ambitious program to tackle the “important but not obvious” questions in cancer to ensure no stone …

16
Oct

Stat5 Predicts Outcomes for Prostate Cancer Patients after Radical Prostatectomy

Men who had high levels of the activated Stat5 protein in their prostate cancer after a radical prostatectomy were more likely to have a recurrence or die from the disease compared to men who had little to no presence of the growth protein, according to a recent study published in Human Pathology by Jefferson’s Kimmel …

9
Oct

Doubling up on Advanced Prostate Cancer with PARP Inhibitors

A newly discovered function of PARP-1 could be the key to more effective therapeutics to treat advanced prostate cancer patients, a recent preclinical study published in Cancer Discovery by Jefferson’s Kimmel Cancer Center researchers suggests. The team, led by Karen E. Knudsen, Ph.D., Professor in the Departments of Cancer Biology, Urology, & Radiation Oncology at …

20
Sep

Tissue around tumor holds key to fighting triple negative breast cancer

A natural substance found in the surrounding tissue of a tumor may be a promising weapon to stop triple negative breast cancer from metastasizing. A preclinical study published in PLOS ONE September 19 by Thomas Jefferson University researchers found that decorin, a well-studied protein known to help halt tumor growth, induces a series of tumor …

14
Sep

Jefferson and the Eagles Team Up for Prostate Health and Cancer Awareness

September is Prostate Cancer Awareness month, and Thomas Jefferson University Hospitals has again teamed up with the Philadelphia Eagles to educate fans and others about prostate health and to raise cancer awareness. To help kick off the campaign, Jefferson will serve as the presenting partner at the Sunday, September 16 game versus the Baltimore Ravens, with …

13
Sep

KCC Becomes Provisional ECOG Member

In August, The Eastern Cooperative Oncology Group (ECOG) voted to approve Jefferson’s Kimmel Cancer Center and Thomas Jefferson University Hospital as a Provisional Member. ECOG is one of the largest clinical cancer research organizations in the United States, and conducts clinical trials in all types of adult cancers. It constitutes a large network of private …

7
Sep

Dr. Karen Knudsen Led Group Receives Million Dollar Prostate Cancer Foundation Award

A group of investigators led by Dr. Karen Knudsen was awarded a 2-year challenge grant of one million dollars by the Prostate Cancer Foundation.  The details of this award (from the PCF web site) are: 2012 Movember-PCF Challenge Award Lead Investigator: Karen Knudsen, PhD Thomas Jefferson University Title Interrogation of Aberrant DNA Repair in Sporadic …

6
Sep

Dr. Onder Alpdogan and Dr. Jianqing Lin Granted ACS-IRG Awards

Congratulations to Dr. Onder Alpdogan and Dr. Jianqing Lin for each being selected recipients of an ACS-IRG award. The American Cancer Society-Institutional Research Grants (ACS-IRG) are designed to provide seed money to support junior faculty members with an interest in cancer research. The ACS defines junior faculty as investigators at the rank of assistant professor …

5
Sep

Voichita Bar-Ad, M.D., Named Residency Program Director in Jefferson’s Radiation Oncology Department

Voichita Bar-Ad, M.D., an associate professor in the Department of Radiation Oncology at Thomas Jefferson University Hospital and Jefferson’s Kimmel Cancer Center, has been named Residency Program Director. Dr. Bar-Ad is a board-certified radiation oncologist who treats primarily head and neck and gastrointestinal cancer cases. Her research focuses on treatment-related side effects and toxicities, patient quality …

1
Aug

Nicole Simone, M.D., Receives ASTRO Research Award

The American Society for Radiation Oncology (ASTRO) has awarded five physicians with research grants to promote the continued advancement of radiation therapy. One of this year’s recipient for the Junior Faculty Career Research Training Award is Nicole L. Simone, M.D., of the Department of Radiation Oncology at Thomas Jefferson University Hospital. The Junior Faculty Award …

26
Jul

Breast Cancer Patients Who Lack RB Gene Respond Better to Neoadjuvant Chemotherapy

Breast cancer patients whose tumors lacked the retinoblastoma tumor suppressor gene (RB) had an improved pathological response to neoadjuvant chemotherapy, researchers at Thomas Jefferson University Hospital and the Kimmel Cancer Center at Jefferson report in a retrospective study published in a recent online issue of Clinical Cancer Research. Many breast cancer patients undergo neoadjuvant therapy …

14
Jun

How Aging Normal Cells Fuel Tumor Growth and Metastasis

It has long been known that cancer is a disease of aging, but a molecular link between the two has remained elusive. Now, researchers at the Kimmel Cancer Center at Jefferson (KCC) have shown that senescence (aging cells which lose their ability to divide) and autophagy (self-eating or self-cannibalism) in the surrounding normal cells of …

14
Jun

Kimmel Cancer Center at Jefferson Hosts a Patient Symposium Focusing on Melanoma of the Eye

The Kimmel Cancer Center will host the inaugural “Eyes on a Cure: Patient and Caregiver Symposium”  on June 16 and 17. The symposium will bring uveal melanoma patients, caregivers, and researchers from around the world together to offer educational sessions, support groups led by oncology social workers, sessions on complementary therapies, as well as informal …

13
Jun

HIV Drug May Slow Down Metastatic Triple-Negative Breast Cancer

Researchers at the Kimmel Cancer Center, led by Dr. Richard G. Pestell have discovered that FDA-approved HIV drugs may stop triple-negative breast cancer from spreading to other organs in pre-clinical models. These results were originally reported in Cancer Research. Recent articles about this discovery have also appeared in NewsWise and the Philadelphia Inquirer.

7
Jun

HIV drug may slow down metastatic breast cancer

The HIV drugs known as CCR5 antagonists may also help prevent aggressive breast cancers from metastasizing, researchers from the Kimmel Cancer Center at Jefferson suggest in a preclinical study published in a recent issue of Cancer Research. Such drugs target the HIV receptor CCR5, which the virus uses to enter and infect host cells, and …

31
May

ASCO: Younger Colon Cancer Patients Have Worse Prognosis at Diagnosis, Yet Better Survival

Younger patients with colorectal cancer were more likely to present advanced stage tumors at diagnosis and metastasize much sooner, yet had better than or equal survival to patients 50 and older, according to data being presented at the 2012 American Society of Clinical Oncology Annual Meeting in Chicago. (Abstract #3621, Monday, June 4, 8:00 AM …

31
May

ASCO: Liver Metastases and its Prognostic Significance in Men With Metastatic Castration-Refractory Prostate Cancer

Liver metastases predicts shorter overall survival in men with metastatic castration-refractory prostate cancer (mCRPC), according to data being presented at the 2012 American Society of Clinical Oncology Annual Meeting in Chicago. (Abstract # 4655, Sunday, June 3, 8:00 AM – 12:00 PM CST, S Hall A2). In a phase III trial, lead study author William …

23
May

Data Continues to Support Provenge’s Overall Survival Benefit in Prostate Cancer Patients

This article was adapted from an OncLive story posted on May 21, 2012. Leonard G. Gomella, M.D, chair of the Department of Urology at Thomas Jefferson University Hospital and director of Clinical Affairs, Jefferson’s Kimmel Cancer Center, was part of the team to present new findings from the IMPACT trial looking at the immunotherapy sipuleucel-T …

Page 4 of 11